Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNotes PayablesPayablesProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China SXT Pharmaceuticals (SXTC) Total Liabilities (2018 - 2025)

China SXT Pharmaceuticals has reported Total Liabilities over the past 8 years, most recently at $6.1 million for Q3 2025.

  • For Q3 2025, Total Liabilities fell 61.66% year-over-year to $6.1 million; the TTM value through Sep 2025 reached $6.1 million, down 61.66%, while the annual FY2025 figure was $6.2 million, 32.33% down from the prior year.
  • Total Liabilities for Q3 2025 was $6.1 million at China SXT Pharmaceuticals, down from $6.2 million in the prior quarter.
  • Over five years, Total Liabilities peaked at $18.6 million in Q1 2021 and troughed at $6.1 million in Q3 2025.
  • A 5-year average of $11.4 million and a median of $9.4 million in 2023 define the central range for Total Liabilities.
  • Biggest five-year swings in Total Liabilities: surged 67.82% in 2024 and later crashed 61.66% in 2025.
  • Year by year, Total Liabilities stood at $8.9 million in 2021, then dropped by 17.87% to $7.3 million in 2022, then surged by 30.44% to $9.5 million in 2023, then surged by 67.82% to $16.0 million in 2024, then crashed by 61.66% to $6.1 million in 2025.
  • Business Quant data shows Total Liabilities for SXTC at $6.1 million in Q3 2025, $6.2 million in Q1 2025, and $16.0 million in Q3 2024.